Latest & greatest articles for fluconazole

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on fluconazole or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on fluconazole and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for fluconazole

41. Amphotericin B vs fluconazole for controlling fungal infections in neutropenic cancer patients.

Amphotericin B vs fluconazole for controlling fungal infections in neutropenic cancer patients. BACKGROUND: Systemic fungal infection is considered to be an important cause of morbidity and mortality in cancer patients, particularly those with neutropenia. Antifungal drugs are often given prophylactically, or to patients with persistent fever. OBJECTIVES: To compare the effect of fluconazole and amphotericin B on morbidity and mortality in patients with cancer complicated by neutropenia. SEARCH (...) STRATEGY: MEDLINE and Cochrane Library (March 2000). Letters, abstracts, and unpublished trials. The industry and authors were contacted. SELECTION CRITERIA: Randomised trials comparing fluconazole with amphotericin B. DATA COLLECTION AND ANALYSIS: Data on mortality, invasive fungal infection, colonisation, use of additional (escape) antifungal therapy and adverse effects leading to discontinuation of therapy were extracted by both authors independently. MAIN RESULTS: Thirteen trials (2977 patients

Cochrane2000

42. Economic analysis of fluconazole versus amphotericin B for the treatment of candidemia in non-neutropenic patients

Economic analysis of fluconazole versus amphotericin B for the treatment of candidemia in non-neutropenic patients Economic analysis of fluconazole versus amphotericin B for the treatment of candidemia in non-neutropenic patients Economic analysis of fluconazole versus amphotericin B for the treatment of candidemia in non-neutropenic patients Dranitsaris G, Phillips P, Rotstein C, Puodziunas A, Shafran S, Garber G, Smaill F, Salit I, Miller M, Williams K, Conly J, Singer J, Ioannou S Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Treatment of candidemia using two intravenous antifungal therapies, either fluconazole (FLU) or amphotericin B(AMB). Type of intervention Treatment. Economic study type Cost-effectiveness

NHS Economic Evaluation Database.1998

43. Fluconazole as prophylaxis against fungal infection in patients with advanced HIV infection

Fluconazole as prophylaxis against fungal infection in patients with advanced HIV infection Fluconazole as prophylaxis against fungal infection in patients with advanced HIV infection Fluconazole as prophylaxis against fungal infection in patients with advanced HIV infection Manfredi R, Mastroianni A, Coronado O V, Chiodo F Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Fluconazole treatment for the prevention of systemic fungal diseases related to the AIDS. Type of intervention Primary prevention and treatment. Economic study type Cost-effectiveness analysis. Study population HIV-infected subjects with advanced infection and a CD4+ lymphocyte count below 0.20x 10?9 Setting Hospital. The economic study was carried out

NHS Economic Evaluation Database.1997

44. Fluconazole compared with endoscopy for human immunodeficiency virus-infected patients with esophageal symptoms

Fluconazole compared with endoscopy for human immunodeficiency virus-infected patients with esophageal symptoms Fluconazole compared with endoscopy for human immunodeficiency virus-infected patients with esophageal symptoms Fluconazole compared with endoscopy for human immunodeficiency virus-infected patients with esophageal symptoms Wilcox C M, Alexander L N, Clark W S, Thompson S E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS (...) EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Fluconazole compared with endoscopy for Human Immunodeficiency Virus (HIV)-infected patients. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population HIV-infected patients with esophageal symptoms. No further details were given. Setting Hospital

NHS Economic Evaluation Database.1996

45. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group.

A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. 7854376 1995 03 16 1995 03 16 2013 11 21 0028-4793 332 11 1995 Mar 16 The New England journal of medicine N. Engl. J. Med. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus (...) infection. NIAID AIDS Clinical Trials Group. 700-5 Cryptococcal meningitis and other serious fungal infections are common complications in patients infected with the human immunodeficiency virus (HIV). Fluconazole is effective for long-term suppression of many fungal infections, but its effectiveness as primary prophylaxis had not been adequately evaluated. We conducted a prospective, randomized trial that compared fluconazole (200 mg per day) with clotrimazole troches (10 mg taken five times daily

NEJM1995

46. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute.

A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. 7935701 1994 11 17 1994 11 17 2013 11 21 0028-4793 331 20 1994 Nov 17 The New England journal of medicine N. Engl. J. Med. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. 1325-30 Amphotericin B (...) has long been the standard treatment for candidemia, but its use is complicated by its toxicity. More recently, fluconazole, a water-soluble triazole with activity against candida species and little toxicity, has become available. We conducted a multicenter randomized trial that compared amphotericin B with fluconazole as treatment for candidemia. To be eligible, patients had to have a positive blood culture for candida species, a neutrophil count > or = 500 per cubic millimeter, and no major

NEJM1994

47. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group.

Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. 1727236 1992 01 10 1992 01 10 2013 11 21 0028-4793 326 2 1992 Jan 09 The New England journal of medicine N. Engl. J. Med. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. 83-9 Intravenous (...) amphotericin B, with or without flucytosine, is usually standard therapy for cryptococcal meningitis in patients with the acquired immunodeficiency syndrome (AIDS). Fluconazole, an oral triazole agent, represents a promising new approach to the treatment of cryptococcal disease. In a randomized multicenter trial, we compared intravenous amphotericin B with oral fluconazole as primary therapy for AIDS-associated acute cryptococcal meningitis. Eligible patients, in all of whom the diagnosis had been

NEJM1992

48. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group.

A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. 1538722 1992 03 27 1992 03 27 2013 11 21 0028-4793 326 12 1992 Mar 19 The New England journal of medicine N. Engl. J. Med. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The (...) NIAID AIDS Clinical Trials Group and Mycoses Study Group. 793-8 After primary treatment for cryptococcal meningitis, patients with the acquired immunodeficiency syndrome (AIDS) require some form of continued suppressive therapy to prevent relapse. We conducted a multicenter, randomized trial that compared fluconazole (200 mg per day given orally) with amphotericin B (1 mg per kilogram of body weight per week given intravenously) in patients with AIDS who had completed primary therapy

NEJM1992

49. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation.

A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. 1542320 1992 04 07 1992 04 07 2013 11 21 0028-4793 326 13 1992 Mar 26 The New England journal of medicine N. Engl. J. Med. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. 845-51 Superficial and systemic fungal infections are a major problem among severely immunocompromised patients who undergo bone marrow (...) transplantation. We performed a double-blind, randomized, multicenter trial in which patients receiving bone marrow transplants were randomly assigned to receive placebo or fluconazole (400 mg daily). Fluconazole or placebo was administered prophylactically from the start of the conditioning regimen until the neutrophil count returned to 1000 per microliter, toxicity was suspected, or a systemic fungal infection was suspected or proved. By the end of the treatment period, 67.2 percent of the 177 patients

NEJM1992

50. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group.

A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. 1992319 1991 03 11 1991 03 11 2013 11 21 0028-4793 324 9 1991 Feb 28 The New England journal of medicine N. Engl. J. Med. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative (...) Treatment Group. 580-4 In patients with the acquired immunodeficiency syndrome (AIDS), the rate of relapse after primary treatment for cryptococcal meningitis remains high. We conducted a controlled, double-blind trial to evaluate the efficacy of maintenance therapy with fluconazole. At entry into the study, all participants had sterile cultures of cerebrospinal fluid, blood, and urine after following a standardized course of therapy for culture-proved cryptococcal meningitis. The patients were randomly

NEJM1991

51. Comparison of fluconazole and ketoconazole for oropharyngeal candidiasis in AIDS.

Comparison of fluconazole and ketoconazole for oropharyngeal candidiasis in AIDS. 2564563 1989 05 05 1989 05 05 2015 06 16 0140-6736 1 8641 1989 Apr 08 Lancet (London, England) Lancet Comparison of fluconazole and ketoconazole for oropharyngeal candidiasis in AIDS. 746-8 In a randomised, double-blind study the efficacy and toxicity of oral fluconazole 50 mg daily and ketoconazole 200 mg daily were compared for the treatment of oropharyngeal candidiasis in patients (...) with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex (ARC). 20 episodes (18 patients) were treated with fluconazole and 20 episodes (19 patients) with ketoconazole. Pretreatment clinical features and laboratory test results were similar in both groups. 17 episodes (85%) in the fluconazole group and 16 (80%) in the ketoconazole group could be evaluated. There was clinical cure at the end of therapy in all fluconazole-treated and 12 of 16 (75%) ketoconazole-treated episodes. Cultures were negative at the end

Lancet1989